Methods and compositions for treating melanoma
US-2024424002-A1 · Dec 26, 2024 · US
US2017081726A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2017081726-A1 |
| Application number | US-201615268938-A |
| Country | US |
| Kind code | A1 |
| Filing date | Sep 19, 2016 |
| Priority date | Jun 22, 2012 |
| Publication date | Mar 23, 2017 |
| Grant date | — |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
This disclosure describes, in one aspect, a method that, in general, includes analyzing a tumor tissue sample from a subject for expression of at least two biomarkers, wherein a predetermined ratio of expression of the at least two biomarkers identifies the tumor tissue sample as coming from a subject having a particular subtype of lymphoma; and identifying the subject as having a particular subtype of lymphoma.
Opening claim text (preview).
1 - 25 . (canceled) 26 . A kit for determining prognosis of a subject, the kit comprising: reagents for measuring expression of a plurality of predictive coding regions in a sample from the subject, the plurality of predictive coding regions comprising at least one of: a combination of CD28 and ABCA5; or a combination of CCDC3 and SMOC2. 27 . The kit of claim 26 wherein the reagents for measuring expression of a plurality of predictive coding regions comprises reagents for performing Northern blotting, nuclease protection assay, DNA microarray, serial analysis of gene expression, quantitative reverse transcription-polymerase chain reaction (RT-PCR), differential-display RT-PCR, massively parallel signature sequencing, or real-time quantitative PCR. 28 . The kit of claim 26 wherein the reagents for measuring expression of a plurality of predictive coding regions comprises reagents for performing protein expression analysis. 29 - 34 . (canceled)
Prognosis of disease development · CPC title
acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase · CPC title
attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin {(digitoxin A61K31/7048)} · CPC title
Amides of phosphorus acids · CPC title
Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.